Small-molecule modulators of TRP-P8 activity
View Patent ↗Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression.
1. A method for treatment of benign prostatic hyperplasia BPH), an enlarged prostate, acute urinary retention, or symptoms thereof or reducing prostate size in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I-E:
wherein A, B, C, and D are independently selected from the group consisting of CR 1 and N; wherein at least one of A, B, C, and D is CR 1 ; wherein R 1 is selected from the group consisting of H, alkyl, heteroalkyl, aryl, arylalkyl, and halogen; and wherein when two adjacent of A, B, C, and D are CR 1 , the two R 1 s may combine to form a single aryl, cycloalkyl, or heterocycloalkyl group; and
R 2 is selected from the group consisting of alkyl, alkoxy and amide;
R 3 is selected from the group consisting of H, methyl and —C=NH(NH2);
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 wherein R 1 is H.
3. The method of claim 1 wherein R 1 is CF 3 or halogen.
4. The method of claim 1 wherein R 2 is selected from the group consisting of methylene, ethylene, propylene, and butylene.
5. The method of claim 4 wherein R 2 is ethylene and R 3 is H.
6. The method of claim 1 wherein R 1 is methoxy.
7. The method of claim 1 wherein R 3 is H, methyl or —C=NH(NH 2 ).
8. The method of claim 1 , said method further comprising administration of one or more benign prostatic hyperplasia (BPH) therapeutic agents.
9. The method of claim 1 wherein R 3 is H.
10. The method of claim 1 wherein the compound is 1-(2-Amino-ethyl)-1-(2-isopropyl-5-methyl-cyclohexanecarbonyl)-1,3-dihydro-benzoimidazol -2-one.
11. The method of claim 1 wherein the compound is 3-(2-Amino-ethyl)-1-(2-isopropyl-5-methyl-cyclohexanecarbonyl)-2-oxo-2,3-dihydro-1H -benzoimidazol-5-carboxylic acid amide.
12. A method for treatment of benign prostatic hyperplasia (BPH), an enlarged prostate, acute urinary retention, or symptoms thereof or reducing prostate size in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I-E:
wherein the moiety:
is selected from the group consisting of 3-(2-amino-ethyl)-5-methoxy-1,3-dihydro-benzoimidazol-2-one, 3-(2-Amino-ethyl)-5-(3-hydroxy-propoxy)-1,3-dihydro -benzoimidazol-2-one, 3-(2-Amino-ethyl)-5-ethoxy-1,3-dihydro-benzoimidazol-2-one, 3-(2-Amino-ethyl)-5-methanesulfonyl-1,3-dihydro-benzoimidazol-2-one, 3-(2-Amino-ethyl)-5-(2-hydroxy-ethoxy)-1,3-dihydro-benzoimidazol-2-one, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H -benzoimidazole-5-carboxylic acid amide, 3-(2-Amino-ethyl)-5-methylsulfanyl-1,3-dihydro -benzoimidazol-2-one, 3-(2-Amino-ethyl)-5-methanesulfinyl-1,3-dihydro-benzoimidazol-2-one, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid (2-diethylamino -ethyl)-amide, 3-(2-Amino-propyl)-2,3-dihydro-benzoimidazol-2-one, [3-(2-Amino-ethyl)-2-oxo -2,3-dihydro-1H-benzoimidazol-5-yloxy]-acetonitrile, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H -benzoimidazole-5-carboxylic acid ethylamide, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H -benzoimidazole-5-carboxylic acid pyridin-3-ylamide, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H -benzoimidazole-5-carboxylic acid (2-methoxy-ethyl)-amide, 1-(2-Amino-ethyl)-1,3-dihydro -benzoimidazol-2-one, 1-(2-Amino-ethyl)-1,3-dihydro-naphtho[2,3-d]imidazol-2-one, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethyl) -amide, 3-(2-Amino-ethyl)-5-propoxy-1,3-dihydro-benzoimidazol-2-one, 3-(2-Amino-ethyl)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H -benzoimidazole-4-carboxylic acid (2-diethylamino-ethyl)-amide, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid pyridin-4-ylamide, 3-(2-Amino-ethyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-one, 1-(3-Amino-propyl)-1,3-dihydro-benzoimidazol-2-one, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid phenylamide, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid [2-(2-hydroxy-ethoxy) -ethyl]-amide, 1-(2-Amino-ethyl)-5-trifluoromethyl1-1,3-dihydro-benzoimidazol-2-one, 1-(2-Amino-ethyl)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro -1H-benzoimidazole-5-carboxylic acid benzylamide, 3-(2-Amino-ethyl)-5-(morpholine-4-carbonyl)-1,3-dihydro-benzoimidazol-2-one, 3-(2-Amino-ethyl)-5-(2-oxo-2-phenyl-ethoxy)-1,3-dihydro-benzoimidazol-2-one, 3-(2-methylamino-ethyl)-1,3-dihydro-benzoimidazol-2-one, 3-(2-Amino-ethyl)-5-butoxy-1,3-dihydro-benzoimidazol-2-one, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxyiic acid methyl-phenyl-amide, 4-[3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carbonyl]-piperazine-1-carboxylic acid ethyl ester, 3-(2-Amino-ethyl)-2-oxo-2,3,dihydro-1H-benzoimidazole-5-carboxylic acid diethylamide, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid phenethyl-amide, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro- 1H-benzoimidazole-5-carboxylic acid (2-hydroxy-1-hydroxymethyl-2-phenyl-ethyl)-amide, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H -benzoimidazole-5-carboxylic acid carbamoylmethyl-amide, 3-(2-Amino-ethyl)-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, N-{2-[2-oxo-2,3-dihydro-benzoimidazol-1-yl]-ethyl}-guanidine, 3-(2-Amino-ethyl)-5-benzyloxy-1,3-dihydro-benzoimidazol-2-one, and 1-(4-Amino-butyl)-1,3-dihydro-benzoimidazol-2-one.
13. The method of claim 12 wherein said compound is 3-(2-Amino-ethyl)-1-(2-isopropyl-5-methyl-cyclohexanecarbonyl)-5-methoxy-1,3-dihydro -benzoimidazol-2-one.
14. A method of using a compound of Formula I-E:
wherein A, B, C, and D are independently selected from the group consisting of CR 1 and N;
wherein at least one of A, B, C, and D is CR 1 ; wherein R 1 is selected from the group consisting of H, alkyl, heteroalkyl, aryl, arylalkyl, and halogen; and wherein when two adjacent of A, B, C, and D are CR 1 , the two R 1 s may combine to form a single aryl, cycloalkyl, or heterocycloalkyl group; and
R 2 is selected from the group consisting of alkyl, alkoxy and amide;
R 3 is selected from the group consisting of H, methyl and —C=NH(NH 2 );
or a pharmaceutically acceptable salt thereof, to prepare a medicament useful for treating benign prostatic hyperplasia (BPH).
15. A method for treatment of benign prostatic hyperplasia (BPH), an enlarged prostate, acute urinary retention, or symptoms thereof or reducing prostate size in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I-E:
wherein A, B, C, and D are independently selected from the group consisting of CR 1 and N;
wherein at least one of A, B, C, and D is CR 1 ; wherein R 1 is selected from the group consisting of:
—OR i ;
—SR ii ;
—S(O)R iii ;
—S(O) 2 R iv ; wherein R i ,R ii ,R iii and R iv are selected from the group consisting of methyl, hydroxymethyl, ethyl, hydroxyethyl, propyl, hydroxypropyl, butyl, hydroxybutyl, acetonitrile, phenyl, phenylrnethoxy, phenylethoxy, phenylpropoxy, phenylbutoxy, and benzyl;
—C(O)NR v R vi , wherein R v and R vi are independently selected from the group consisting of H, methyl, hydroxymethyl, ethyl, hydroxyethyl, propyl, hydroxypropyl, butyl, hydroxybutyl, diethylaminoethyl, phenyl, pyridinyl, methoxyethyl, hydroxyethoxyethyl, benzyl, methylphenyl, phenylethyl, hydroxyhydroxymethylphenylethyl, carbamoylmethyl, and hydroxymethyl hydroxyethyl; or R v and R vi together form morpholine, piperazine, or piperazine ethyl ester;
R 2 is selected from the group consisting of alkyl, alkoxy and amide; and
R 3 is selected from the group consisting of H, methyl and —C=NH(NH 2 ); or a pharmaceutically acceptable salt thereof.
16. The method of claim 15 wherein R 1 is —OR i and wherein R i is selected from the group consisting of methyl, hydroxymethyl, ethyl, hydroxyethyl, propyl, hydroxypropyl, butyl, hydroxybutyl, acetonitrile, phenyl, phenylrnethoxy, phenylethoxy, phenylpropoxy, phenylbutoxy, and benzyl.
17. The method of claim 15 wherein R 1 is —SR ii and wherein R ii is selected from the group consisting of methyl, hydroxymethyl, ethyl, hydroxyethyl, propyl, hydroxypropyl, butyl, hydroxybutyl, acetonitrile, phenyl, phenylrnethoxy, phenylethoxy, phenylpropoxy, phenylbutoxy, and benzyl.
18. The method of claim 15 wherein R 1 is —S(O)R iii and wherein R iii is selected from the group consisting of methyl, hydroxymethyl, ethyl, hydroxyethyl, propyl, hydroxypropyl, butyl, hydroxybutyl, acetonitrile, phenyl, phenylrnethoxy, phenylethoxy, phenylpropoxy, phenylbutoxy, and benzyl.
19. The method of claim 15 wherein R 1 is —S(O) 2 R iv and wherein R iv is selected from the group consisting of methyl, hydroxymethyl, ethyl, hydroxyethyl, propyl, hydroxypropyl, butyl, hydroxybutyl, acetonitrile, phenyl, phenylrnethoxy, phenylethoxy, phenylpropoxy, phenylbutoxy, and benzyl.
20. The method of claim 15 wherein R 1 is —C(O)NR v R vi , wherein R v and R vi are independently selected from the group consisting of H, methyl, hydroxymethyl, ethyl, hydroxyethyl, propyl, hydroxypropyl, butyl, hydroxybutyl, diethylaminoethyl, phenyl, pyridinyl, methoxyethyl, hydroxyethoxyethyl, benzyl, methylphenyl, phenylethyl, hydroxyhydroxymethylphenylethyl, carbamoylmethyl, and hydroxymethyl hydroxyethyl.
21. The method of claim 15 wherein R 1 is —C(O)NR v R vi , wherein R v and R vi together form morpholine, piperazine, or piperazine ethyl ester.